# Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference Canonical URL: https://biopharmsignal.com/news/NVCT/nuvectis-pharma-to-participate-at-the-h-c-wainwright-27th-annual-global-investment-conference Ticker: NVCT Company: Nuvectis Pharma Source: Nuvectis Pharma Published: 2025-09-04 07:30 EST Original Source URL: https://www.pressviewer.com ## Summary

Fort Lee, NJ, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development ## Article Body Fort Lee, NJ, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that senior management will participate in the... ## Recent Company News - 2025-09-04 07:30 EST — [Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference](https://biopharmsignal.com/news/NVCT/nuvectis-pharma-to-participate-at-the-h-c-wainwright-27th-annual-global-investment-conference) — Source: Nuvectis Pharma - 2025-08-11 16:30 EST — [Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900](https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-the-initiation-of-the-phase-1b-program-for-nxp900) — Source: Nuvectis Pharma - 2025-08-05 07:30 EST — [Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights](https://biopharmsignal.com/news/NVCT/nuvectis-pharma-inc-reports-second-quarter-2025-financial-results-and-business-highlights) — Source: Nuvectis Pharma - 2025-07-31 07:45 EST — [Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study](https://biopharmsignal.com/news/NVCT/nuvectis-pharma-provides-final-clinical-data-update-from-the-nxp800-phase-1b-study-in-ovarian-cancer-and-reports-completion-of-the-nxp900-phase-1a-dose-escalation-study) — Source: Nuvectis Pharma - 2025-07-08 08:00 EST — [Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies](https://biopharmsignal.com/news/NVCT/nuvectis-pharma-announces-successful-completion-of-a-drug-drug-interaction-study-in-healthy-volunteers-supporting-nxp900-s-potential-as-a-combination-partner-with-leading-therapies) — Source: Nuvectis Pharma ## Related News - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec) - 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)